New diabetes drug aims to slow kidney failure in High-Risk patients

NCT ID NCT07116928

Not yet recruiting Disease control Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding ganagliflozin tablets to standard care can slow kidney disease progression in 1,244 adults with type 2 diabetes and chronic kidney disease. Participants will take either ganagliflozin or a placebo daily for 120 weeks. The main goal is to measure changes in kidney function over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ganagliflozin
What this could lead to: If it works, this could provide a new treatment option to help preserve kidney function and delay the need for dialysis or transplant in people with type 2 diabetes and chronic kidney disease.
What could go wrong: This is a phase 4 trial, so the drug is already approved, but it may not show significant benefit over placebo. Side effects could include dehydration, urinary tract infections, or other risks common to this class of drugs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CKD - CHRONIC KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CKD - CHRONIC KIDNEY DISEASE T2DM (TYPE 2 DIABETES MELLITUS)

Contacts and locations

Locations

Shanghai sixth People's Hospital

Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.